Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving carboplatin together with everolimus and prednisone may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin together with everolimus and prednisone works in treating patients with metastatic prostate cancer that progressed after docetaxel.

Key facts

Study ID

NCT01051570

Run by

Barbara Ann Karmanos Cancer Institute

People needed

26

Starts

2010-02-01

Expected to finish

2013-09-01

Last updated by the study team

2020-12-01

Who can join

Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Northshore University Health System — Evanston, Illinois, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Weisberg Cancer Treatment Center — Farmington Hills, Michigan, United States
• Cancer Institute of New Jersey — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.